Long-established in the Medical Devices & Instruments industry, NovoCure Ltd (NVCR, Financial) has enjoyed a stellar reputation. However, it has recently witnessed a decline of 30.34%, juxtaposed with a three-month change of -73.07%. Fresh insights from the GuruFocus Score Rating hint at potential headwinds. Notably, its diminished rankings in financial strength, growth, and valuation suggest that the company might not live up to its historical performance. Join us as we dive deep into these pivotal metrics to unravel the evolving narrative of NovoCure Ltd.
Understanding the GF Score
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with a lower GF Score. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
- 1. Financial strength rank: 5/10
- 2. Profitability rank: 3/10
- 3. Growth rank: 7/10
- 4. GF Value rank: 4/10
- 5. Momentum rank: 1/10
Based on the above method, GuruFocus assigned NovoCure Ltd the GF Score of 61 out of 100, which signals poor future outperformance potential.
NovoCure Ltd: A Snapshot of Its Business
NovoCure Ltd, with a market cap of $2.21 billion, operates in the healthcare sector of the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.
Financial Strength Breakdown
NovoCure Ltd's financial strength indicators present some concerning insights about the company's balance sheet health. The company's Altman Z-Score is just 2.42, which is below the safe threshold of 2.99. Although this does not imply immediate danger of financial distress, the stock may face some financial struggles if the Altman Z-score drops below 1.81.
NovoCure Ltd's low Profitability rank can also raise warning signals. NovoCure Ltd's Operating Margin has declined over the past five years ((-30,713.00%)), as shown by the following data: 2018: -13.57; 2019: -0.26; 2020: 6.15; 2021: -8.29; 2022: -16.65; . With a Piotroski F-Score of 2, NovoCure Ltd's financial health appears concerning. This score, rooted in Joseph Piotroski's nine-point scale, evaluates a firm's profitability, liquidity, and operating efficiency. Given its rating, NovoCure Ltd might be facing challenges in these areas.
Considering the company's financial strength, profitability, and growth metrics, the GuruFocus Score Rating highlights the firm's unparalleled position for potential underperformance. While NovoCure Ltd has a history of strong performance, its current financial indicators suggest that it may struggle to maintain this trend. As value investors, it's crucial to consider these factors when making investment decisions.
GuruFocus Premium members can find more companies with strong GF Scores using the following screener link: GF Score Screen